Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 3/20 | 0.53 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553738 | 0.85 | C5AR1 (0.55) | C5AR1MCOLN3MAPTLMNAPOLB | |
| SCHEMBL6831818 | 0.83 | C5AR1 (0.49) | C5AR1MCOLN3MAPTLMNAPOLB | |
| SCHEMBL12595919 | 0.72 | EPAS1 (0.46) | LMNATSHRTDP1 | |
| SCHEMBL10051874 | 0.71 | EPAS1 (0.55) | LMNA | |
| SCHEMBL6861935 | 0.71 | MAPT (0.58) | C5AR1MCOLN3MAPTLMNACA12 | |
| SCHEMBL6553328 | 0.70 | GLA (0.41) | C5AR1GLACYP2C9KDM4ETDP1 | |
| SCHEMBL2892311 | 0.70 | C5AR1 (0.53) | C5AR1MAPTLMNACA12CA9 | |
| SCHEMBL6553128 | 0.69 | HCRTR2 (0.53) | GLA | |
| SCHEMBL6553183 | 0.69 | PSEN1 (0.49) | C5AR1GLA | |
| SCHEMBL13211334 | 0.69 | EPAS1 (0.46) | LMNATSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023938-A1 | Sulfonamide derivatives | TABUCHI TAKANORI (JP) | 2004-02-05 | — | — | US | disclosed |
| US-6586617-B1 | Nontoxic microbiocides such as 4'-chloro-N-ethyl-2'-nitro-p-toluenesulfonanilide, for agricultural or horticultural, prepared by alkylation or nitration | SUMITOMO CHEMICAL TAKEDA AGRO COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1174028-A1 | SULFONAMIDE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023938-A1 | Sulfonamide derivatives | FPR1, MRM1, SULT1E1 | C5AR1 822/4885MCOLN3 3672/4885MAPT 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.